Structure of MK-1775
CAS No.: 955365-80-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Adavosertib (AZD-1775; MK-1775) is characterized by potent inhibition against Wee1, exhibiting an IC50 of 5.2 nM.
Synonyms: Adavosertib; AZD1775
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 955365-80-7 |
Formula : | C27H32N8O2 |
M.W : | 500.60 |
SMILES Code : | O=C1N(CC=C)N(C2=NC(C(C)(O)C)=CC=C2)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=NC=C31 |
Synonyms : |
Adavosertib; AZD1775
|
MDL No. : | MFCD17215200 |
InChI Key : | BKWJAKQVGHWELA-UHFFFAOYSA-N |
Pubchem ID : | 24856436 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302 |
Precautionary Statements: | P280-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
AML cell lines | 200-400 nM | 72 h | MK-1775 induced apoptosis in AML cells, accompanied by decreased phosphorylation of CDK1 and CDK2 and increased DNA double-strand breaks. | PMC4237862 |
CTS and U937 cell lines | 500 nM | 48 h | MK-1775 treatment abrogated the G2/M cell cycle checkpoint, accompanied by increased γH2AX and decreased p-CDK1 and p-CDK2. | PMC4237862 |
MCF7 cells | 200 nM | 72 h | MK-1775 in combination with Alisertib selectively induced apoptosis in RB-deficient cells by inhibiting WEE1 and AURK. | PMC10680093 |
T47D cells | 200 nM | 48 h | MK-1775 in combination with Alisertib selectively induced apoptosis in RB-deficient cells by inhibiting WEE1 and AURK. | PMC10680093 |
PCI-13 cells | 0.25 μM | 48 h | MK-1775 significantly enhanced the cytotoxic effect of cisplatin in p53-deficient HNSCC cells, as evidenced by the shift in the cisplatin response curve and a significant reduction in IC values. | PMC4557970 |
SKM-1 | 100 nM | 24 h | MK-1775 increased caspase 3 and PARP activity in SKM-1 cells | PMC10304360 |
SKM-1 | 100 nM | 72 h | MK-1775 increased cytotoxicity in SKM-1 cells | PMC10304360 |
SKM-1 | 100 nM | 72 h | MK-1775 inhibited the proliferation of SKM-1 cells | PMC10304360 |
SKM-1 | 100 nM | 72 h | MK-1775 alone inhibited the proliferation of SKM-1 cells, increased cellular cytotoxicity and caspase 3/7 activity. | PMC10304360 |
Ba/F3-NRAS-G12D cells | 75 nM | 2 h | MK-1775 combined with mTOR inhibitors inhibited the phosphorylation of AKT, 4E-BP1, and S6K. | PMC4667710 |
Ba/F3-KRAS-G12D cells | 75 nM | 2 h | MK-1775 combined with mTOR inhibitors inhibited the phosphorylation of AKT, 4E-BP1, and S6K. | PMC4667710 |
NB4 cells | 75 nM | 2 h | MK-1775 inhibited the phosphorylation of CDK1. | PMC4667710 |
Ba/F3-NRAS-G12D cells | 75 nM | 2 h | MK-1775 combined with mTOR inhibitors suppressed phosphorylation of AKT, 4E-BP1, and S6K | PMC4667710 |
Ba/F3-KRAS-G12D cells | 75 nM | 2 h | MK-1775 combined with mTOR inhibitors suppressed phosphorylation of AKT, 4E-BP1, and S6K | PMC4667710 |
NB4 cells | 75 nM | 2 h | MK-1775 suppressed phosphorylation of cdc2 (CDK1) | PMC4667710 |
ASPC-1 | 13.2 μM | 48 h | MK-1775 treatment caused S phase or both S and G2/M phase arrest, accompanied by increased H2AX phosphorylation, indicating increased DNA double-strand breaks, and activation of CHK1 | PMC4282784 |
BxPC-3 | 0.8 μM | 48 h | MK-1775 treatment caused S phase or both S and G2/M phase arrest, accompanied by increased H2AX phosphorylation, indicating increased DNA double-strand breaks, and activation of CHK1 | PMC4282784 |
CFPAC-1 | 3.3 μM | 48 h | MK-1775 treatment caused S phase or both S and G2/M phase arrest, accompanied by increased H2AX phosphorylation, indicating increased DNA double-strand breaks, and activation of CHK1 | PMC4282784 |
HPAC | 0.5 μM | 48 h | MK-1775 treatment caused S phase or both S and G2/M phase arrest, accompanied by increased H2AX phosphorylation, indicating increased DNA double-strand breaks, and activation of CHK1 | PMC4282784 |
MIAPaCa-2 | 0.5 μM | 48 h | MK-1775 treatment caused S phase or both S and G2/M phase arrest, accompanied by increased H2AX phosphorylation, indicating increased DNA double-strand breaks, and activation of CHK1 | PMC4282784 |
PANC-1 | 10.6 μM | 48 h | MK-1775 treatment caused S phase or both S and G2/M phase arrest, accompanied by increased H2AX phosphorylation, indicating increased DNA double-strand breaks, and activation of CHK1 | PMC4282784 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | MCF7 xenograft models | Oral | 30 mg/kg | Every other day for 3 weeks | MK-1775 in combination with Alisertib significantly inhibited the growth of RB-deficient tumors, while having limited effect on RB-proficient tumors. | PMC10680093 |
nude mice | oral tongue cancer model | oral | 30 mg/kg | twice weekly for 4 weeks | MK-1775 significantly enhanced the antitumor efficacy of cisplatin in high-risk TP53 mutant HNSCC tumors, as evidenced by significant delay in tumor growth. | PMC4557970 |
mice | inducible mutant Kras lung cancer model | oral | 10 mg/kg | once daily for one week | The combination of MK-1775 and Torin 2 significantly suppressed tumor growth. | PMC4667710 |
BALB/c nude mice | BxPC-3 xenograft model | oral gavage | 20 mg/kg | twice a week for three weeks | MK-1775 alone had modest delay of tumor growth, while combination with panobinostat significantly delayed tumor growth with 58.7% inhibition | PMC4282784 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03385655 | Prostate Cancer | Phase 2 | Recruiting | December 31, 2020 | Canada, Alberta ... More >> Cross Cancer Institute Recruiting Edmonton, Alberta, Canada, T6G 1Z2 Contact: Michael Kolinsky 780 432-8762 Canada, British Columbia BCCA - Vancouver Cancer Centre Recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Kim Chi 604 877-6000 ext 2746 Canada, Nova Scotia QEII Health Sciences Centre Recruiting Halifax, Nova Scotia, Canada, B3H 1V7 Contact: Robyn J. Macfarlane 902 473-6106 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Som Mukherjee 905 387-9495 ext 64605 London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 5W9 Contact: Eric W. Winquist 519 685-8261 Ottawa Hospital Research Institute Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: Michael Ong 613 737-7700 ext 75051 University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Adrian Sacher 416 946-4501 ext 3550 Canada, Quebec CHUM-Centre Hospitalier de l'Universite de Montreal Recruiting Montreal, Quebec, Canada, H2X 3E4 Contact: Fred Saad 514 890-8000 ext 27466 The Jewish General Hospital Recruiting Montreal, Quebec, Canada, H3T 1E2 Contact: Cristiano Ferrario 514 398-8307 Canada, Saskatchewan Allan Blair Cancer Centre Recruiting Regina, Saskatchewan, Canada, S4T 7T1 Contact: Muhammad Salim 306 766-2691 Saskatoon Cancer Centre Recruiting Saskatoon, Saskatchewan, Canada, S7N 4H4 Contact: Nayyer Iqbal 306 655-2710 Less << |
NCT02546661 | Muscle Invasive Bladder Cancer | Phase 1 | Recruiting | March 27, 2020 | - |
NCT02813135 | Children, Adolescents and Youn... More >>g Adults With Refractory or Recurrent Malignancies Less << | Phase 1 Phase 2 | Recruiting | January 2022 | France ... More >> Gustave Roussy Recruiting Villejuif, Val De Marne, France, 94805 Contact: Birgit Geoerger, MD 1 42 11 4661 ext +33 birgit.geoerger@gustaveroussy.fr Contact: Xavier Paoletti, MD 1 42 11 6564 ext +33 xavier.paoletti@gustaveroussy.fr Principal Investigator: Birgit Geoerger, MD Germany University Children's Hospitalermany Not yet recruiting Heidelberg, Germany Contact: Olaf Witt, MD 6221 56 4555 ext +49 O.Witt@Dkfz-Heidelberg.de Italy Fondazione IRCCS Istituto Nazionale dei Tumori Not yet recruiting Milan, Italy Contact: Michela Casanova, MD 02 23 90 25 94 ext +39 Michela.Casanova@istitutotumori.mi.it Netherlands Erasmus MC, Sophia Children's Hospital Not yet recruiting Rotterdam, Netherlands Contact: Michel Zwaan, MD 10 703 6691 ext +31 c.m.zwaan@erasmusmc.nl Spain Unidad de Oncología Pediátrica Hospital Niño Jesús Not yet recruiting Madrid, Spain, 28009 Contact: Francisco Bautista, MD 915 035 900 ext +43 franciscojose.bautista@salud.madrid.org United Kingdom Pediatric and Adolescent Oncology The Royal Marsden Hospital Not yet recruiting Sutton, United Kingdom Contact: Lynley Marshall, MD 208 661 3678 ext +44 Lynley.Marshall@icr.ac.uk Less << |
NCT02465060 | Advanced Malignant Solid Neopl... More >>asm Bladder Carcinoma Breast Carcinoma Cervical Carcinoma Colon Carcinoma Colorectal Carcinoma Endometrial Carcinoma Esophageal Carcinoma Gastric Carcinoma Glioma Head and Neck Carcinoma Kidney Carcinoma Liver and Intrahepatic Bile Duct Carcinoma Lung Carcinoma Lymphoma Malignant Uterine Neoplasm Melanoma Ovarian Carcinoma Pancreatic Carcinoma Plasma Cell Myeloma Prostate Carcinoma Rectal Carcinoma Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Cervical Carcinoma Recurrent Colon Carcinoma Recurrent Colorectal Carcinoma Recurrent Esophageal Carcinoma Recurrent Gastric Carcinoma Recurrent Glioma Recurrent Head and Neck Carcinoma Recurrent Liver Carcinoma Recurrent Lung Carcinoma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Ovarian Carcinoma Recurrent Pancreatic Carcinoma Recurrent Plasma Cell Myeloma Recurrent Prostate Carcinoma Recurrent Rectal Carcinoma Recurrent Skin Carcinoma Recurrent Thyroid Gland Carcinoma Recurrent Uterine Corpus Carcinoma Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Plasma Cell Myeloma Skin Carcinoma Thyroid Gland Carcinoma Uterine Corpus Cancer Less << | Phase 2 | Recruiting | - | - |
NCT02937818 | Platinum Refractory Extensive-... More >>Stage Small Cell Lung Carcinoma Less << | Phase 2 | Recruiting | January 22, 2021 | Germany ... More >> Research Site Not yet recruiting Gauting, Germany, 82131 Hungary Research Site Recruiting Kecskemét, Hungary, 6000 Research Site Recruiting Miskolc, Hungary, 3529 Research Site Recruiting Székesfehérvár, Hungary, 8000 Poland Research Site Recruiting Poznań, Poland, 60-569 Research Site Recruiting Warszawa, Poland, 02-781 Spain Research Site Recruiting Sevilla, Spain, 41009 Research Site Recruiting Valencia, Spain, 46009 Ukraine Research Site Recruiting Dnipropetrovsk, Ukraine, 49102 Research Site Recruiting Ivano-Frankivsk, Ukraine, 76018 Research Site Not yet recruiting Kirovograd, Ukraine, 25006 Research Site Active, not recruiting Sumy, Ukraine, 40022 Less << |
NCT01827384 | Advanced Malignant Solid Neopl... More >>asm Less << | Not Applicable | Suspended(Scheduled Interim Mo... More >>nitoring) Less << | - | United States, Colorado ... More >> University of Colorado Hospital Aurora, Colorado, United States, 80045 United States, Kentucky University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States, 40536 United States, Maryland National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States, 20892 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT03579316 | Recurrent Fallopian Tube Carci... More >>noma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Less << | Phase 2 | Recruiting | March 31, 2019 | United States, Massachusetts ... More >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Robert L. Coleman 713-745-3357 Principal Investigator: Robert L. Coleman Less << |
NCT03345784 | Endometrioid Adenocarcinoma ... More >> Recurrent Cervical Carcinoma Stage I Uterine Corpus Cancer AJCC v7 Stage I Vaginal Cancer AJCC v6 and v7 Stage IA Uterine Corpus Cancer AJCC v7 Stage IB Cervical Cancer AJCC v6 and v7 Stage IB Uterine Corpus Cancer AJCC v7 Stage IB2 Cervical Cancer AJCC v6 and v7 Stage II Cervical Cancer AJCC v7 Stage II Uterine Corpus Cancer AJCC v7 Stage II Vaginal Cancer AJCC v6 and v7 Stage IIA Cervical Cancer AJCC v7 Stage IIB Cervical Cancer AJCC v6 and v7 Stage III Cervical Cancer AJCC v6 and v7 Stage III Uterine Corpus Cancer AJCC v7 Stage III Vaginal Cancer AJCC v6 and v7 Stage IIIA Cervical Cancer AJCC v6 and v7 Stage IIIA Uterine Corpus Cancer AJCC v7 Stage IIIB Cervical Cancer AJCC v6 and v7 Stage IIIB Uterine Corpus Cancer AJCC v7 Stage IIIC Uterine Corpus Cancer AJCC v7 Less << | Phase 1 | Recruiting | October 18, 2020 | United States, California ... More >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Vanessa A. Kennedy United States, Colorado University of Colorado Hospital Recruiting Aurora, Colorado, United States, 80045 Contact: Site Public Contact 720-848-0650 Principal Investigator: Bradley R. Corr United States, Kentucky University of Kentucky/Markey Cancer Center Recruiting Lexington, Kentucky, United States, 40536 Contact: Site Public Contact 859-257-3379 Principal Investigator: Rachel W. Miller United States, New Jersey Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact 732-235-8675 Principal Investigator: Eugenia Girda Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact 732-235-8675 Principal Investigator: Eugenia Girda United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact 888-275-3853 Principal Investigator: James L. Abbruzzese Canada, Ontario University Health Network-Princess Margaret Hospital Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Site Public Contact 416-946-4501 clinical.trials@uhn.on.ca Principal Investigator: Stephanie Lheureux Less << |
NCT03284385 | Locally Advanced Malignant Sol... More >>id Neoplasm Metastatic Malignant Solid Neoplasm Less << | Phase 2 | Recruiting | August 30, 2021 | United States, California ... More >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Mamta Parikh UCSF Medical Center-Mount Zion Recruiting San Francisco, California, United States, 94115 Contact: Site Public Contact 877-827-3222 Principal Investigator: Rahul R. Aggarwal UCSF Medical Center-Mission Bay Recruiting San Francisco, California, United States, 94158 Contact: Site Public Contact 877-827-3222 Principal Investigator: Rahul R. Aggarwal United States, District of Columbia MedStar Georgetown University Hospital Recruiting Washington, District of Columbia, United States, 20007 Contact: Site Public Contact 202-444-2223 Principal Investigator: Michael J. Pishvaian United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Site Public Contact 410-955-8804 jhcccro@jhmi.edu Principal Investigator: Ana D. De Jesus Acosta United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact 877-726-5130 Principal Investigator: Geoffrey I. Shapiro Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Site Public Contact 888-823-5923 ctsucontact@westat.com Principal Investigator: Geoffrey I. Shapiro Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 617-667-9925 Principal Investigator: Geoffrey I. Shapiro Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 877-442-3324 Principal Investigator: Geoffrey I. Shapiro United States, Missouri Siteman Cancer Center at West County Hospital Recruiting Creve Coeur, Missouri, United States, 63141 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Nikolaos Trikalinos Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Nikolaos Trikalinos Siteman Cancer Center-South County Recruiting Saint Louis, Missouri, United States, 63129 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Nikolaos Trikalinos Siteman Cancer Center at Christian Hospital Recruiting Saint Louis, Missouri, United States, 63136 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Nikolaos Trikalinos Siteman Cancer Center at Saint Peters Hospital Recruiting Saint Peters, Missouri, United States, 63376 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Nikolaos Trikalinos United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Site Public Contact 412-647-8073 Principal Investigator: Nathan Bahary United States, Tennessee Vanderbilt University/Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Site Public Contact 800-811-8480 Principal Investigator: W. K. Rathmell Less << |
NCT02095132 | Central Nervous System Embryon... More >>al Tumor With Rhabdoid Features Central Nervous System Embryonal Tumor, Not Otherwise Specified Central Nervous System Ganglioneuroblastoma Embryonal Tumor With Multilayered Rosettes, C19MC-Altered Pineoblastoma Primary Central Nervous System Neoplasm Recurrent Childhood Central Nervous System Embryonal Neoplasm Recurrent Malignant Solid Neoplasm Recurrent Medulloblastoma Recurrent Neuroblastoma Recurrent Rhabdomyosarcoma Refractory Malignant Solid Neoplasm Refractory Medulloblastoma Refractory Neuroblastoma Refractory Rhabdomyosarcoma Less << | Phase 1 Phase 2 | Recruiting | - | - |
NCT03330847 | Metastatic Triple Negative Bre... More >>ast Cancer Less << | Phase 2 | Recruiting | January 20, 2021 | - |
NCT02576444 | Cancer | Phase 2 | Recruiting | March 2019 | United States, Connecticut ... More >> Yale Cancer Center Recruiting New Haven, Connecticut, United States, 06520-8028 Contact: Alexandra Minnella 203-737-3446 alexandra.minnella@yale.edu Principal Investigator: Joseph P Eder, MD United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Brian Beardslee 617-632-5638 brian_beardslee@dfci.harvard.edu Principal Investigator: Geoffrey Shapiro, MD United States, Ohio Cleveland Clinic Taussig Cancer Institute Recruiting Cleveland, Ohio, United States, 44195 Contact: Nancy Frazier 216-444-5531 frazien@ccf.org Principal Investigator: Davendra PS Sohal, MD, MPH United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Tom Leonard-Martin 615-936-6726 Thomas.Leonard-Martin@vumc.org Principal Investigator: Vicki L Keedy, MD Less << |
NCT02659241 | Ovarian Cancer ... More >> Fallopian Tube Cancer Peritoneum Cancer Less << | Early Phase 1 | Recruiting | February 2021 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less << |
NCT02448329 | Advanced Gastric Adenocarcinom... More >>a Less << | Phase 2 | Recruiting | December 2019 | Korea, Republic of ... More >> Samsung Medical center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Yoonjeong Ahn 82-2-2148-7395 younjeong.ahn@samsung.com Principal Investigator: Jeeyun Lee, MD,PhD Less << |
NCT01849146 | Adult Glioblastoma ... More >> Recurrent Glioblastoma Less << | Phase 1 | Recruiting | - | United States, Alabama ... More >> University of Alabama at Birmingham Cancer Center Suspended Birmingham, Alabama, United States, 35233 United States, California UCLA / Jonsson Comprehensive Cancer Center Suspended Los Angeles, California, United States, 90095 UCSF Medical Center-Parnassus Suspended San Francisco, California, United States, 94143 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Suspended Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact 877-726-5130 Principal Investigator: Eudocia Q. Lee Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 877-442-3324 Principal Investigator: Eudocia Q. Lee United States, Michigan Henry Ford Hospital Recruiting Detroit, Michigan, United States, 48202 Contact: Site Public Contact 313-916-1784 Principal Investigator: Tobias Walbert United States, New York Memorial Sloan Kettering Cancer Center Suspended New York, New York, United States, 10065 United States, North Carolina Wake Forest University Health Sciences Recruiting Winston-Salem, North Carolina, United States, 27157 Contact: Site Public Contact 336-713-6771 Principal Investigator: Glenn J. Lesser United States, Ohio Cleveland Clinic Foundation Suspended Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania/Abramson Cancer Center Suspended Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh Cancer Institute (UPCI) Suspended Pittsburgh, Pennsylvania, United States, 15232 Less << |
NCT02666950 | Chronic Myelomonocytic Leukemi... More >>a Myelodysplastic Syndrome With Isolated Del(5q) Myelodysplastic/Myeloproliferative Neoplasm Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << | Phase 2 | Completed | - | United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 Less << |
NCT02906059 | Metastatic Colorectal Cancer | Phase 1 | Recruiting | September 2019 | United States, New York ... More >> Laura and Isaac Perlmutter Cancer Center Recruiting New York, New York, United States, 10016 Contact: Deirdre Cohen, MD 212-731-5656 Deirdre.Cohen@nyumc.org Sub-Investigator: Ping Gu, MD Sub-Investigator: Cynthia Leichman, MD Sub-Investigator: Lawrence Leichman, MD Sub-Investigator: Theresa Ryan, MD Sub-Investigator: Jennifer Wu, MD Less << |
NCT02272790 | Ovarian, Fallopian Tube, Perit... More >>oneal Cancer, P53 Mutation Less << | Phase 2 | Active, not recruiting | December 17, 2018 | United States, Arizona ... More >> Research Site Gilbert, Arizona, United States, 85234 Research Site Tucson, Arizona, United States, 85724 United States, California Research Site La Jolla, California, United States, 92093 Research Site Los Angeles, California, United States, 90095-6996 Research Site San Francisco, California, United States, 94158 United States, Florida Research Site Tampa, Florida, United States, 33612 Research Site West Palm Beach, Florida, United States, 33401 United States, Georgia Research Site Augusta, Georgia, United States, 30912 United States, Massachusetts Research Site Boston, Massachusetts, United States, 02215 United States, New York Research Site New York, New York, United States, 10019 Research Site New York, New York, United States, 10065 United States, Ohio Research Site Cleveland, Ohio, United States, 44195 United States, Oklahoma Research Site Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Research Site Nashville, Tennessee, United States, 37203 United States, Texas Research Site Dallas, Texas, United States, 75390 United States, Wisconsin Research Site Milwaukee, Wisconsin, United States, 53226 Canada, Ontario Research Site Toronto, Ontario, Canada, M5G 2M9 Netherlands Research Site Amsterdam, Netherlands, 1066 CX Less << |
NCT03028766 | Hypopharynx Squamous Cell Carc... More >>inoma Oral Cavity Squamous Cell Carcinoma Larynx Cancer Less << | Phase 1 | Recruiting | December 2019 | United Kingdom ... More >> University Hospital Birmingham Nhs Foundation Trust Recruiting Birmingham, West Midlands, United Kingdom, B15 2TH Principal Investigator: James Good Beatson West of Scotland Cancer Centre Recruiting Glasgow, United Kingdom, G12 0YN Principal Investigator: Stefano Schipani University College London Hospitals Recruiting London, United Kingdom, W1T 7HA Principal Investigator: Martin Forster Clatterbridge Cancer Centre Not yet recruiting Wirral, United Kingdom, CH63 4JY Principal Investigator: Joseph Sacco Less << |
NCT03718143 | Myelofibroses ... More >> Acute Myeloid Leukemia Myelodysplastic Syndromes Less << | Phase 2 | Not yet recruiting | May 1, 2021 | - |
NCT02617277 | Advanced Solid Tumours | Phase 1 | Recruiting | April 8, 2019 | United States, Colorado ... More >> Research Site Recruiting Denver, Colorado, United States, 80218 United States, Florida Research Site Recruiting Sarasota, Florida, United States, 34232 United States, Tennessee Research Site Recruiting Nashville, Tennessee, United States, 37203 Less << |
NCT03253679 | Advanced Malignant Solid Neopl... More >>asm CCNE1 Gene Amplification Refractory Malignant Solid Neoplasm Less << | Phase 2 | Recruiting | September 30, 2020 | United States, Colorado ... More >> University of Colorado Hospital Recruiting Aurora, Colorado, United States, 80045 Contact: Site Public Contact 720-848-0650 Principal Investigator: Brandon D. Bernard United States, New York Columbia University/Herbert Irving Cancer Center Recruiting New York, New York, United States, 10032 Contact: Site Public Contact 212-305-6361 nr2616@cumc.columbia.edu Principal Investigator: Richard D. Carvajal United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact 888-275-3853 Principal Investigator: James L. Abbruzzese United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact 877-312-3961 Principal Investigator: Siqing Fu Less << |
NCT03333824 | Solid Tumours | Phase 1 | Recruiting | June 28, 2019 | United States, Arizona ... More >> Research Site Withdrawn Tucson, Arizona, United States, 85724 United States, California Research Site Withdrawn Los Angeles, California, United States, 90048 Research Site Withdrawn Pasadena, California, United States, 91105 United States, Indiana Research Site Not yet recruiting Indianapolis, Indiana, United States, 46202 United States, Maryland Research Site Withdrawn Silver Spring, Maryland, United States, 20910 United States, Michigan Research Site Recruiting Bingham Farms, Michigan, United States, 48025 Research Site Recruiting Detroit, Michigan, United States, 48202 United States, New Hampshire Research Site Recruiting Lebanon, New Hampshire, United States, 03756 United States, Ohio Research Site Recruiting Cincinnati, Ohio, United States, 45229 United States, Rhode Island Research Site Recruiting Providence, Rhode Island, United States, 02903 United States, South Carolina Research Site Recruiting Greenville, South Carolina, United States, 29605 United States, Texas Research Site Recruiting Dallas, Texas, United States, 75251 Research Site Withdrawn Houston, Texas, United States, 77030 Less << |
NCT02381548 | Acute Myeloid Leukemia ... More >> Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Refractory Acute Myeloid Leukemia Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << | Phase 1 | Terminated | - | United States, Florida ... More >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Less << |
NCT02194829 | Metastatic Pancreatic Adenocar... More >>cinoma Stage III Pancreatic Cancer AJCC v6 and v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Unresectable Pancreatic Carcinoma Less << | Phase 1 Phase 2 | Active, not recruiting | - | United States, Illinois ... More >> Northwestern University Chicago, Illinois, United States, 60611 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 United States, Pennsylvania University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 Less << |
NCT01922076 | Anaplastic Astrocytoma ... More >> Anaplastic Oligoastrocytoma Diffuse Intrinsic Pontine Glioma Diffuse Midline Glioma, H3 K27M-Mutant Glioblastoma Gliosarcoma Untreated Childhood Anaplastic Astrocytoma Untreated Childhood Anaplastic Oligoastrocytoma Untreated Childhood Glioblastoma Untreated Childhood Gliosarcoma Less << | Phase 1 | Recruiting | - | - |
NCT02791919 | CNS 2a CNS 2b... More >> CNS 2c CNS1 Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Myeloid Leukemia Less << | Phase 1 | Withdrawn(Other - Protocol mov... More >>ed to Disapproved) Less << | May 31, 2019 | - |
NCT03012477 | Triple-negative Metastatic Bre... More >>ast Cancer Less << | Phase 2 | Recruiting | December 2024 | United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Steven Isakoff, MD, PhD Contact 617-726-4920 sisakoff@partners.org Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Sara Tolaney, MD, MPH 617-632-3800 stolaney@partners.org Principal Investigator: Sara Tolaney, MD, MPH Less << |
NCT02513563 | Lung Cancer | Phase 2 | Recruiting | October 2020 | United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Germaine Gonzalez-Vazquez 813-745-6636 germaine.gonzalezvazquez@moffitt.org Contact: Jhanelle Gray, M.D. 813-745-7282 jhanelle.gray@moffitt.org Principal Investigator: Jhanelle Gray, M.D. Sub-Investigator: Scott Antonia, M.D., Ph.D. Sub-Investigator: Alberto Chiappori, M.D. Sub-Investigator: Ben Creelan, M.D. Sub-Investigator: Eric Haura, M.D. Sub-Investigator: Tawee Tanvetyanon, M.D. Sub-Investigator: Charles Williams, M.D. Sub-Investigator: Trevor Rose, M.D. Less << |
NCT00648648 | Solid Tumors | Phase 1 | Completed | - | - |
NCT03313557 | Solid Tumors | Phase 1 | Recruiting | August 11, 2020 | United States, Arizona ... More >> Research Site Withdrawn Tucson, Arizona, United States, 85724 United States, California Research Site Withdrawn Los Angeles, California, United States, 90048 Research Site Withdrawn Pasadena, California, United States, 91105 United States, Maryland Research Site Withdrawn Silver Spring, Maryland, United States, 20910 United States, Michigan Research Site Recruiting Bingham Farms, Michigan, United States, 48025 Research Site Recruiting Detroit, Michigan, United States, 48202 United States, New Hampshire Research Site Recruiting Lebanon, New Hampshire, United States, 03756 United States, Ohio Research Site Recruiting Cincinnati, Ohio, United States, 45229 United States, Rhode Island Research Site Recruiting Providence, Rhode Island, United States, 02906 United States, South Carolina Research Site Recruiting Greenville, South Carolina, United States, 29605 United States, Texas Research Site Recruiting Dallas, Texas, United States, 75251 Research Site Withdrawn Houston, Texas, United States, 77030 France Research Site Completed Bordeaux Cedex, France, 33075 Research Site Completed Saint Herblain Cedex, France, 44805 Netherlands Research Site Active, not recruiting Amsterdam, Netherlands, 1066 CX Research Site Active, not recruiting Amsterdam, Netherlands, 1081 HV Research Site Active, not recruiting Maastricht, Netherlands, 6229 HX United Kingdom Research Site Active, not recruiting Glasgow, United Kingdom, G12 0YN Research Site Active, not recruiting Manchester, United Kingdom, M20 4BX Less << |
NCT03315091 | Solid Tumours | Phase 1 | Completed | - | France ... More >> Research Site Bordeaux Cedex, France, 33075 Research Site Saint Herblain, France, 44805 Netherlands Research Site Amsterdam, Netherlands, 1066 CX Research Site Amsterdam, Netherlands, 1081 HV Research Site Maastricht, Netherlands, 6229 HX United Kingdom Research Site Glasgow, United Kingdom, G12 0YN Research Site Manchester, United Kingdom, M20 4BX Less << |
NCT02585973 | Carcinoma, Squamous Cell of He... More >>ad and Neck Less << | Phase 1 | Recruiting | November 2021 | United States, North Carolina ... More >> UNC Lineberger Comprehensive Cancer Center Recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Dan Goldin 919-966-4432 dan_goldin@med.unc.edu Contact: Chris Hilliard 919-966-4432 Chris_Hilliard@med.unc.edu Less << |
NCT02593019 | Small Cell Lung Cancer | Phase 2 | Active, not recruiting | March 2019 | Korea, Republic of ... More >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 Less << |
NCT03668340 | Uterine Cancer | Phase 2 | Recruiting | June 1, 2023 | United States, Massachusetts ... More >> Massachusetts General Hospital Cancer Center Not yet recruiting Boston, Massachusetts, United States, 02214 Contact: Richard T Penson, MD rpenson@partners.org Principal Investigator: Richard T Penson, MD Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Joyce Liu, MD joyce_liu@dfci.harvard.edu Principal Investigator: Joyce Liu, MD Less << |
NCT02511795 | Refractory Solid Tumours ... More >> Relapsed Small Cell Lung Cancer (SCLC) Less << | Phase 1 | Recruiting | September 27, 2019 | United States, Colorado ... More >> Research Site Recruiting Denver, Colorado, United States, 80218 United States, Florida Research Site Recruiting Sarasota, Florida, United States, 34232 United States, New York Research Site Recruiting New York, New York, United States, 10033 United States, Tennessee Research Site Recruiting Nashville, Tennessee, United States, 37203 United States, Texas Research Site Recruiting Houston, Texas, United States, 77030 Canada, Ontario Research Site Active, not recruiting Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT02087176 | - | Terminated(The study was termi... More >>nated early by the sponsor.) Less << | - | - | |
NCT02688907 | Small Cell Lung Cancer | Phase 2 | Terminated(change regimen) | - | Korea, Republic of ... More >> Keunchil Park Seoul, Korea, Republic of, 135-710 Less << |
NCT02482311 | Ovarian Cancer, TNBC, SCLC, Ot... More >>her Solid Tumours Less << | Phase 1 | Active, not recruiting | October 1, 2018 | United States, Arkansas ... More >> Research Site Fayetteville, Arkansas, United States, 72703 United States, California Research Site La Jolla, California, United States, 92093 Research Site Los Angeles, California, United States, 90048 Research Site San Francisco, California, United States, 94115 United States, Florida Research Site Fort Myers, Florida, United States, 33905 United States, Indiana Research Site Indianapolis, Indiana, United States, 46202 United States, Michigan Research Site Detroit, Michigan, United States, 48201 United States, North Carolina Research Site Charlotte, North Carolina, United States, 28204 United States, Oklahoma Research Site Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States, 19104 United States, South Carolina Research Site Greenville, South Carolina, United States, 29605 United States, Tennessee Research Site Nashville, Tennessee, United States, 37203 United States, Texas Research Site Houston, Texas, United States, 77030 United States, Wisconsin Research Site Milwaukee, Wisconsin, United States, 53226 Canada, Alberta Research Site Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia Research Site Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Research Site Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT02101775 | Ovarian Brenner Tumor ... More >> Ovarian Carcinosarcoma Ovarian Clear Cell Cystadenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Cystadenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Cystadenocarcinoma Ovarian Serous Surface Papillary Adenocarcinoma Ovarian Undifferentiated Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Less << | Phase 2 | Active, not recruiting | - | United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 City of Hope South Pasadena South Pasadena, California, United States, 91030 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 Decatur Memorial Hospital Decatur, Illinois, United States, 62526 United States, Indiana Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 Canada, British Columbia BCCA-Cancer Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Ottawa Hospital and Cancer Center-General Campus Ottawa, Ontario, Canada, K1H 8L6 University Health Network Princess Margaret Cancer Center P2C Toronto, Ontario, Canada, M5G 2M9 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec CHUM - Hopital Notre-Dame Montreal, Quebec, Canada, H2L 4M1 Singapore National University Hospital Singapore Singapore, Singapore, 119074 Less << |
NCT02087241 | Previously Untreated Stage IV ... More >>Non-Squamous Non Small Cell Lung Cancer Less << | Phase 2 | Terminated(The sponsor decided... More >> to terminate the study.) Less << | - | United States, Colorado ... More >> Research Site Englewood, Colorado, United States United States, Florida Research Site Fort Myers, Florida, United States Research Site Orlando, Florida, United States United States, Illinois Research Site Peoria, Illinois, United States United States, Indiana Research Site Fort Wayne, Indiana, United States United States, Kansas Research Site Wichita, Kansas, United States United States, Ohio Research Site Cincinnati, Ohio, United States United States, Tennessee Research Site Nashville, Tennessee, United States Less << |
NCT02087241 | - | Terminated(The sponsor decided... More >> to terminate the study.) Less << | - | - | |
NCT02087176 | Previously Treated Non Small C... More >>ell Lung Cancer Less << | Phase 2 | Terminated(The study was termi... More >>nated early by the sponsor.) Less << | - | United States, Alabama ... More >> Research Site Birmingham, Alabama, United States United States, Arizona Research Site Scottsdale, Arizona, United States United States, Arkansas Research Site Fayetteville, Arkansas, United States United States, Colorado Research Site Englewood, Colorado, United States United States, Florida Research Site Orlando, Florida, United States United States, Kansas Research Site Wichita, Kansas, United States United States, Kentucky Research Site Louisville, Kentucky, United States United States, North Carolina Research Site Durham, North Carolina, United States United States, Ohio Research Site Cincinnati, Ohio, United States United States, Pennsylvania Research Site Pittsburgh, Pennsylvania, United States United States, Tennessee Research Site Nashville, Tennessee, United States United States, Wisconsin Research Site Milwaukee, Wisconsin, United States Less << |
NCT02610075 | Locally Advanced Solid Tumours... More >> Metastatic Solid Tumours Ovarian Cancer Less << | Phase 1 | Completed | - | United States, Arizona ... More >> Research Site Scottsdale, Arizona, United States, 85258 United States, Colorado Research Site Denver, Colorado, United States, 80218 United States, Tennessee Research Site Nashville, Tennessee, United States, 32705 Less << |
NCT02207010 | Glioblastoma ... More >>GBM Less << | Early Phase 1 | Active, not recruiting | May 2018 | United States, Arizona ... More >> Barrow Neurological Institute at St. Joseph's Hospital Medical Center Phoenix, Arizona, United States, 85013 Less << |
NCT02196168 | Recurrent Hypopharyngeal Squam... More >>ous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Laryngeal Verrucous Carcinoma Recurrent Lip and Oral Cavity Squamous Cell Carcinoma Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Recurrent Oral Cavity Verrucous Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary Stage IV Hypopharyngeal Squamous Cell Carcinoma Stage IVA Laryngeal Squamous Cell Carcinoma Stage IVA Laryngeal Verrucous Carcinoma Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IVA Oral Cavity Verrucous Carcinoma Stage IVA Oropharyngeal Squamous Cell Carcinoma Stage IVB Laryngeal Squamous Cell Carcinoma Stage IVB Laryngeal Verrucous Carcinoma Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IVB Oral Cavity Verrucous Carcinoma Stage IVB Oropharyngeal Squamous Cell Carcinoma Stage IVC Laryngeal Squamous Cell Carcinoma Stage IVC Laryngeal Verrucous Carcinoma Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IVC Oral Cavity Verrucous Carcinoma Stage IVC Oropharyngeal Squamous Cell Carcinoma Tongue Carcinoma Less << | Phase 2 | Terminated(Inadequate accrual ... More >>rate) Less << | - | Canada, Ontario ... More >> Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less << |
NCT02508246 | Head and Neck Squamous Cell Ca... More >>rcinoma Less << | Phase 1 | Active, not recruiting | - | United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Less << |
NCT02196168 | - | Terminated(Inadequate accrual ... More >>rate) Less << | - | - | |
NCT01357161 | Ovarian Cancer | Phase 2 | Completed | - | - |
NCT02341456 | Advanced Solid Tumours | Phase 1 | Completed | - | Australia ... More >> Research Site Liverpool, Australia, 2170 Research Site Melbourne, Australia, 3004 Japan Research Site Kashiwa, Japan, 277-8577 Research Site Sapporo-shi, Japan, 003-0804 Korea, Republic of Research Site Seoul, Korea, Republic of, 03080 Research Site Seoul, Korea, Republic of, 05505 Research Site Seoul, Korea, Republic of, 06351 Less << |
NCT01357161 | - | Completed | - | - | |
NCT01076400 | Cervical Cancer | Phase 1 Phase 2 | Terminated(The sponsor permane... More >>ntly suspended new enrollment into the trial and discontinued the study; which was not related to any concerns over product safety.) Less << | - | - |
NCT02037230 | Adenocarcinoma of the Pancreas | Phase 1 Phase 2 | Active, not recruiting | January 2022 | United States, Michigan ... More >> University of Michigan Hospital Ann Arbor, Michigan, United States, 48109 Less << |
NCT01076400 | - | Terminated(The sponsor permane... More >>ntly suspended new enrollment into the trial and discontinued the study; which was not related to any concerns over product safety.) Less << | - | - | |
NCT01047007 | Solid Tumors | Phase 1 | Terminated(The study has been ... More >>terminated due to business reasons.) Less << | - | - |
NCT01047007 | - | Terminated(The study has been ... More >>terminated due to business reasons.) Less << | - | - | |
NCT01748825 | Neoplasms Lym... More >>phoma Less << | Phase 1 | Active, not recruiting | September 27, 2020 | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
NCT01164995 | Epithelial Ovarian Cancer | Phase 2 | Unknown | September 2013 | Netherlands ... More >> Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066CX Contact: Jan HM Schellens, MD, PhD j.slijkerman@nki.nl Principal Investigator: Jan HM Schellens, MD, PhD Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.00mL 0.40mL 0.20mL |
9.99mL 2.00mL 1.00mL |
19.98mL 4.00mL 2.00mL |